Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...152153154155156157158159160161162...401402»
  • ||||||||||  Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Home-based Progressive Resistance Exercise to Enhance Physical Performance of Older Adults With Possible Sarcopenia (clinicaltrials.gov) -  Nov 2, 2022   
    P=N/A,  N=42, Active, not recruiting, 
    These results demonstrate muscle regeneration and functional recovery of mdx via autophagy activation following TMSC-myocyte TP. Recruiting --> Active, not recruiting | N=200 --> 42 | Trial completion date: Apr 2024 --> Dec 2023 | Trial primary completion date: Apr 2024 --> Dec 2022
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  Using Bedside Ultrasound to Screen for Sarcopenia in Older Adults (clinicaltrials.gov) -  Nov 2, 2022   
    P=N/A,  N=152, Completed, 
    Recruiting --> Active, not recruiting | N=200 --> 42 | Trial completion date: Apr 2024 --> Dec 2023 | Trial primary completion date: Apr 2024 --> Dec 2022 Not yet recruiting --> Completed | Trial completion date: Apr 2023 --> Apr 2022 | Trial primary completion date: Dec 2022 --> Dec 2021
  • ||||||||||  Review, Journal:  Autophagy in striated muscle diseases. (Pubmed Central) -  Nov 1, 2022   
    Herein, we summarize how autophagy alterations are linked to cardiac and skeletal muscle defects and how these alterations occur. We further discuss potential pharmacological and genetic interventions to regulate autophagy activities and their applications in cardiac and skeletal muscle diseases.
  • ||||||||||  Clinical data, Journal:  Impact of skeletal muscle loss during conversion therapy on clinical outcomes in lavage cytology positive patients with gastric cancer. (Pubmed Central) -  Nov 1, 2022   
    P2
    Cox multifactorial analysis found that pre-treatment sarcopenia [overall survival (OS): Hazard Ratio (HR) =6.341, 95%CI: 1.269-18.943, p=0.001; progression-free survival (PFS): HR=8.212, 95%CI: 1.569-36.582, p=0.001], newly developed sarcopenia after conversion therapy (OS: HR=3.189, 95%CI: 1.023-9.811, p=0.012; PFS: HR=3.084, 95%CI: 1.042-14.236, p=0.013) and the presence of SML during treatment (OS: HR=10.234, 95%CI: 2.532-54.231, p=0.002; PFS: HR=9.562, 95%CI: 2.341-38.092, p=0.002) were independent risk factor for OS and PFS in GC-CY patients. Pre-treatment sarcopenia and the presence of SML during treatment are strongly correlated with the immediate and long-term outcomes of GC-CY patients and can be used as imaging markers to predict the treatment efficacy and prognosis of patients in clinical practice.
  • ||||||||||  Retrospective data, Journal:  Prognostic Value of Sarcopenia and Myosteatosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma. (Pubmed Central) -  Nov 1, 2022   
    The results point to the need for enhancing muscle mass, measured by appendicular lean mass index, while reducing fat mass and maintaining good bone mineralization in long-term survivors of ALL to ensure the integrity of healthy bones. Myosteatosis was associated with poor OS and RFS in patients with resectable PDAC who underwent curative surgery.
  • ||||||||||  Enrollment open, Trial completion date, Trial primary completion date:  Sarcopenia and Physiology Assessments in Cancer Patients (clinicaltrials.gov) -  Nov 1, 2022   
    P=N/A,  N=639, Recruiting, 
    Patients with low amount of the muscle should be treated based on proper risk assessment. Unknown status --> Recruiting | Trial completion date: Mar 2022 --> Mar 2024 | Trial primary completion date: Mar 2021 --> Mar 2024
  • ||||||||||  Biomarker, Trial completion:  Creatine-Guanidinoacetic Acid Supplementation for Sarcopenia (CREGAAS) (clinicaltrials.gov) -  Nov 1, 2022   
    P=N/A,  N=30, Completed, 
    Unknown status --> Recruiting | Trial completion date: Mar 2022 --> Mar 2024 | Trial primary completion date: Mar 2021 --> Mar 2024 Active, not recruiting --> Completed
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Sarcopenia and Risk of Falls in Patients With Major Chronic Diseases (clinicaltrials.gov) -  Nov 1, 2022   
    P=N/A,  N=186, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | N=320 --> 186 | Trial primary completion date: Jun 2022 --> Sep 2022
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Trial completion date:  Is Gait Speed and Sarcopenia Prognostic in Chronic Respiratory Disease? (clinicaltrials.gov) -  Nov 1, 2022   
    P=N/A,  N=565, Completed, 
    Recruiting --> Completed | N=320 --> 186 | Trial primary completion date: Jun 2022 --> Sep 2022 Active, not recruiting --> Completed | Trial completion date: Jul 2022 --> Apr 2022
  • ||||||||||  Review, Journal:  Connected APA tools and prostate cancer: Literature review and experience feedback (Pubmed Central) -  Oct 31, 2022   
    New tools, such as digital and connected ones, are now developed to overcome barriers to the implementation and daily practice of physical activity (e.g., distance between home and hospital). The aim of this article was to provide an overview of different connected tools that offer exercise training and monitoring programmes in prostate cancer.
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment closed:  PRIMe: Protein Recommendation to Increase Muscle (clinicaltrials.gov) -  Oct 31, 2022   
    P=N/A,  N=50, Active, not recruiting, 
    The aim of this article was to provide an overview of different connected tools that offer exercise training and monitoring programmes in prostate cancer. Recruiting --> Active, not recruiting
  • ||||||||||  Journal:  Single-cell sequencing deconvolutes cellular responses to exercise in human skeletal muscle. (Pubmed Central) -  Oct 30, 2022   
    The transcriptional regulation of these contractile elements upon differentiation was validated in vitro on primary myoblast cells. The cell type-specific adaptive mechanisms induced by exercise presented here contribute to the understanding of the skeletal muscle adaptations triggered by physical activity and may ultimately have implications for physiological and pathological processes affecting skeletal muscle, such as sarcopenia, cachexia, and glucose homeostasis.
  • ||||||||||  Journal:  The prevalence of sarcopenia in patients with rheumatological pathology (Pubmed Central) -  Oct 29, 2022   
    Future studies are necessary to clarify the pathophysiology of sarcopenia and develop effective interventions for sarcopenia in patients with lung cancer. Sarcopenia occurs in a third of hospitalized rheumatological patients.
  • ||||||||||  Journal:  Locomotive syndrome: from paradigms to clinical reality (Pubmed Central) -  Oct 29, 2022   
    Today, there is a clear understanding that drug therapy should be long-term, include comprehensive support for muscle tissue, balance training, and mandatory cognitive-behavioral therapy. Maximum safety of long-term drug therapy can be ensured by the use of vital micronutrients, which include highly purified forms of chondroitin sulfate and glucosamine sulfate, which have a wide range of anti-inflammatory and regenerative effects.